RT Journal Article
SR Electronic
T1 Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.23.20138289
DO 10.1101/2020.06.23.20138289
A1 Lucas, Carolina
A1 Wong, Patrick
A1 Klein, Jon
A1 Castro, Tiago B.R.
A1 Silva, Julio
A1 Sundaram, Maria
A1 Ellingson, Mallory K.
A1 Mao, Tianyang
A1 Oh, Ji Eun
A1 Israelow, Benjamin
A1 Tokuyama, Maria
A1 Lu, Peiwen
A1 Venkataraman, Arvind
A1 Park, Annsea
A1 Mohanty, Subhasis
A1 Wang, Haowei
A1 Wyllie, Anne L.
A1 Vogels, Chantal B.F.
A1 Earnest, Rebecca
A1 Lapidus, Sarah
A1 Ott, Isabel M.
A1 Moore, Adam J.
A1 Muenker, M. Catherine
A1 Fournier, John B.
A1 Campbell, Melissa
A1 Odio, Camila D.
A1 Casanovas-Massana, Arnau
A1 ,
A1 Herbst, Roy
A1 Shaw, Albert C.
A1 Medzhitov, Ruslan
A1 Schulz, Wade L.
A1 Grubaugh, Nathan D.
A1 Cruz, Charles Dela
A1 Farhadian, Shelli
A1 Ko, Albert I.
A1 Omer, Saad B.
A1 Iwasaki, Akiko
YR 2020
UL http://medrxiv.org/content/early/2020/06/27/2020.06.23.20138289.abstract
AB Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19)1–4. Yet, longitudinal immunological correlates of disease outcome remain unclear. Here, we serially analysed immune responses in 113 COVID-19 patients with moderate (non-ICU) and severe (ICU) disease. Immune profiling revealed an overall increase in innate cell lineages with a concomitant reduction in T cell number. We identify an association between early, elevated cytokines and worse disease outcomes. Following an early increase in cytokines, COVID-19 patients with moderate disease displayed a progressive reduction in type-1 (antiviral) and type-3 (antifungal) responses. In contrast, patients with severe disease maintained these elevated responses throughout the course of disease. Moreover, severe disease was accompanied by an increase in multiple type 2 (anti-helminths) effectors including, IL-5, IL-13, IgE and eosinophils. Unsupervised clustering analysis of plasma and peripheral blood leukocyte data identified 4 immune signatures, representing (A) growth factors, (B) type-2/3 cytokines, (C) mixed type-1/2/3 cytokines, and (D) chemokines that correlated with three distinct disease trajectories of patients. The immune profile of patients who recovered with moderate disease was enriched in tissue reparative growth factor signature (A), while the profile for those with worsened disease trajectory had elevated levels of all four signatures. Thus, we identified development of a maladapted immune response profile associated with severe COVID-19 outcome and early immune signatures that correlate with divergent disease trajectories.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Womens Health Research at Yale Pilot Project Program (AI, AR), Fast Grant from Emergent Ventures at the Mercatus Center, Mathers Foundation, and the Ludwig Family Foundation, the Department of Internal Medicine at the Yale School of Medicine, Yale School of Public Health and Beatrice Kleinberg Neuwirth Fund. A.I. is an Investigator of the Howard Hughes Medical Institute. C.L. is a Pew Latin American Fellow. P.Y is supported by Gruber Foundation and the NSF. B.I is supported by NIAID 2T32AI007517-16. CBFV is supported by NOW Rubicon 019.181EN.004.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, Protocol ID. 2000027690). Informed consents were obtained from all enrolled patients and healthcare workers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study will be made openly available in public repositories.